先健科技(1302.HK)創歷史新高 年內累漲超110%
格隆匯11月23日丨繼上週五大漲24.58%後,先健科技(1302.HK)今日再度高開高走,一度漲9.03%報3.26港元,創歷史新高價,市值超140億港元。該股年內累漲超110%。格隆匯平台近日推出深度分析文章《集採下的思索與機會》指出,對於先健科技而言,作為全球第二大,金磚四國最大的先心封堵器供應商以及全球前三的動脈介入支架供應商,創新研發投入不斷加大,創新基因也正在構築長坡厚雪。在過去十年當中,公司已經累計12個產品進入綠色通道,成為國內醫療器械當中僅次於微創醫療獲批的公司。伴隨着重磅產品鐵基系列產品明年開始陸續獲批上市,鐵基技術平台即將迎來收穫期。詳情可點擊下列鏈接。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.